Spyre Therapeutics, Inc. $SYRE Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company trimmed its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 12.5% during the first quarter, HoldingsChannel.com reports. The firm owned 112,841 shares of the company’s stock after selling 16,172 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Spyre Therapeutics were worth $5,692,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Summit Securities Group LLC purchased a new stake in shares of Spyre Therapeutics during the 1st quarter worth about $28,000. KBC Group NV purchased a new position in Spyre Therapeutics in the first quarter valued at approximately $69,000. Persistent Asset Partners Ltd acquired a new position in Spyre Therapeutics during the fourth quarter valued at approximately $74,000. ABS Direct Equity Fund LLC acquired a new position in Spyre Therapeutics during the first quarter valued at approximately $141,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Spyre Therapeutics by 61.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,770 shares of the company’s stock valued at $124,000 after buying an additional 1,435 shares in the last quarter. 80.39% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Spyre Therapeutics

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: Spyre reported a second-quarter loss of $0.36 per share, substantially narrower than the analyst consensus estimate of $0.76. The earnings beat suggests better-than-expected cost management and helped improve investor sentiment. SYRE’s Q2 Loss Narrower Than Expected, Pipeline Progresses
• Positive Sentiment: The company highlighted progress across its Phase 2 development pipeline and upcoming clinical data readouts. These catalysts are particularly important for Spyre because the company remains focused on advancing its therapies rather than generating near-term profits. Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
• Positive Sentiment: Wedbush raised its price target from $100 to $130 and maintained an “Outperform” rating. Guggenheim also increased its target from $115 to $130 and kept a “Buy” rating, signaling that analysts see additional upside from Spyre’s pipeline and upcoming clinical milestones. Analyst price-target updates

Wall Street Analysts Forecast Growth

SYRE has been the subject of several recent research reports. Citigroup increased their price objective on shares of Spyre Therapeutics from $64.00 to $97.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Guggenheim lifted their target price on shares of Spyre Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday. BTIG Research upped their price target on shares of Spyre Therapeutics from $98.00 to $112.00 and gave the stock a “buy” rating in a research report on Monday, June 15th. Wall Street Zen downgraded Spyre Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, April 26th. Finally, Jefferies Financial Group raised their price objective on Spyre Therapeutics from $47.00 to $85.00 and gave the company a “buy” rating in a research report on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $110.15.

Insiders Place Their Bets

In other Spyre Therapeutics news, Director Michael Thomas Henderson sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $100.00, for a total value of $2,000,000.00. Following the transaction, the director directly owned 68,606 shares of the company’s stock, valued at $6,860,600. This represents a 22.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Cameron Turtle sold 15,000 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $95.51, for a total value of $1,432,650.00. Following the transaction, the chief executive officer owned 567,540 shares of the company’s stock, valued at approximately $54,205,745.40. This trade represents a 2.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 199,167 shares of company stock worth $16,327,042 in the last quarter. Company insiders own 15.69% of the company’s stock.

Spyre Therapeutics Price Performance

Shares of SYRE stock opened at $104.35 on Thursday. The company’s fifty day moving average price is $89.91 and its two-hundred day moving average price is $64.66. The firm has a market capitalization of $9.18 billion, a P/E ratio of -53.51 and a beta of 3.03. Spyre Therapeutics, Inc. has a 12 month low of $14.51 and a 12 month high of $108.14.

Spyre Therapeutics (NASDAQ:SYRE) last announced its earnings results on Tuesday, August 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.40. On average, sell-side analysts anticipate that Spyre Therapeutics, Inc. will post -2.86 EPS for the current year.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.